PL2001556T3 - Związki tioniny i ich zastosowanie - Google Patents

Związki tioniny i ich zastosowanie

Info

Publication number
PL2001556T3
PL2001556T3 PL07712962T PL07712962T PL2001556T3 PL 2001556 T3 PL2001556 T3 PL 2001556T3 PL 07712962 T PL07712962 T PL 07712962T PL 07712962 T PL07712962 T PL 07712962T PL 2001556 T3 PL2001556 T3 PL 2001556T3
Authority
PL
Poland
Prior art keywords
thioninium
compounds
thioninium compounds
Prior art date
Application number
PL07712962T
Other languages
English (en)
Inventor
Claude Michel Wischik
Janet Elizabeth Rickard
Charles Robert Harrington
David Horsley
John Mervyn David Storey
Colin Marshall
James Peter Sinclair
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of PL2001556T3 publication Critical patent/PL2001556T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL07712962T 2006-03-29 2007-03-28 Związki tioniny i ich zastosowanie PL2001556T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78669906P 2006-03-29 2006-03-29
EP07712962.5A EP2001556B1 (en) 2006-03-29 2007-03-28 Thioninium compounds and their use
PCT/GB2007/001107 WO2007110630A1 (en) 2006-03-29 2007-03-28 Thioninium compounds and their use

Publications (1)

Publication Number Publication Date
PL2001556T3 true PL2001556T3 (pl) 2015-03-31

Family

ID=38163667

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14185157T PL2853293T3 (pl) 2006-03-29 2007-03-28 Związki tioniny i ich zastosowanie
PL07712962T PL2001556T3 (pl) 2006-03-29 2007-03-28 Związki tioniny i ich zastosowanie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL14185157T PL2853293T3 (pl) 2006-03-29 2007-03-28 Związki tioniny i ich zastosowanie

Country Status (13)

Country Link
EP (2) EP2853293B1 (pl)
JP (1) JP5184507B2 (pl)
CN (2) CN103641794B (pl)
AU (1) AU2007231127B2 (pl)
CA (1) CA2645919C (pl)
DK (2) DK2853293T3 (pl)
ES (2) ES2525001T3 (pl)
HR (2) HRP20141261T1 (pl)
MY (2) MY162640A (pl)
PL (2) PL2853293T3 (pl)
PT (2) PT2001556E (pl)
SI (2) SI2001556T1 (pl)
WO (1) WO2007110630A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
AU2008265045B2 (en) * 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
EP3689346B1 (en) 2008-12-10 2024-01-24 WisTa Laboratories Ltd. 3,6-disubstituted xanthylium salts for treating tauopathies
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
US8785434B2 (en) 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
CN102690244A (zh) * 2011-03-22 2012-09-26 中国科学院上海生命科学研究院 调节α-突触核蛋白积聚的物质及其制药用途
GB201317702D0 (en) * 2013-10-07 2013-11-20 Wista Lab Ltd Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
GB201512678D0 (en) 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
GB201621817D0 (en) 2016-12-21 2017-02-01 Wista Lab Ltd Methods of chemical synthesis
BR112021000802A2 (pt) 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
US12215234B2 (en) * 2019-09-21 2025-02-04 RK Pharma Solutions LLC Process for the purification of methylene blue
GB202010652D0 (en) 2020-07-10 2020-08-26 Wista Lab Ltd Anti-tau antibodies
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
WO2024063700A1 (en) 2022-09-21 2024-03-28 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases
GB202500018D0 (en) 2025-01-02 2025-02-19 Wista Lab Ltd Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004915A1 (en) * 1994-08-08 1996-02-22 Albert Einstein College Of Medicine Of Yeshiva University Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
JP2000344685A (ja) * 1999-03-26 2000-12-12 Bf Kenkyusho:Kk アズールa類似化合物によるアミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
BRPI0416928A (pt) * 2003-11-28 2007-01-16 Photopharmica Ltd desenvolvimento de derivados biologicamente ativos de azul de metileno
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物(mtc)などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
WO2006032879A2 (en) 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)

Also Published As

Publication number Publication date
SI2001556T1 (sl) 2014-12-31
SI2853293T1 (en) 2018-03-30
EP2853293A1 (en) 2015-04-01
CN101460222A (zh) 2009-06-17
CA2645919C (en) 2016-05-31
AU2007231127A1 (en) 2007-10-04
PL2853293T3 (pl) 2018-05-30
CN101460222B (zh) 2013-12-04
MY172157A (en) 2019-11-15
DK2001556T3 (da) 2014-11-10
AU2007231127B2 (en) 2013-03-14
HRP20141261T1 (xx) 2015-03-13
MY162640A (en) 2017-06-30
CN103641794A (zh) 2014-03-19
ES2525001T3 (es) 2014-12-16
WO2007110630A1 (en) 2007-10-04
EP2853293B1 (en) 2017-11-22
EP2001556B1 (en) 2014-10-01
PT2853293T (pt) 2018-02-13
CA2645919A1 (en) 2007-10-04
DK2853293T3 (en) 2018-01-22
HK1121084A1 (en) 2009-04-17
PT2001556E (pt) 2014-12-09
HK1208000A1 (en) 2016-02-19
JP5184507B2 (ja) 2013-04-17
HRP20180204T1 (hr) 2018-03-09
CN103641794B (zh) 2016-09-21
JP2009531405A (ja) 2009-09-03
ES2659030T3 (es) 2018-03-13
EP2001556A1 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
TWI561237B (en) Substituted dihydropyrazolones and their use
IL244442B (en) Compounds of converted acylanilides and their use
GB0701426D0 (en) Compounds and their use
PL2853293T3 (pl) Związki tioniny i ich zastosowanie
IL194899A0 (en) Amino-ethyl-amino-aryl (aeaa) compounds and their use
IL195086A0 (en) Pyrrolopyrimidine compounds and their uses
IL198010A0 (en) Phenylpropionamide compounds and the use thereof
GB0611115D0 (en) Compounds and their use
GB0621160D0 (en) Compounds and uses thereof
EP2124908A4 (en) CONNECTIONS AND ITS USE
GB0605107D0 (en) Use
EP2120563A4 (en) CONNECTIONS AND ITS USES
EP2099459A4 (en) COMPOUNDS AND USES THEREOF
GB0718718D0 (en) Compound and use thereof
IL192820A0 (en) Novel compounds and use thereof
GB0624105D0 (en) Use
GB0619611D0 (en) Compounds and their use
EP2120957A4 (en) COMPOUNDS AND USES THEREOF
HU0600122D0 (en) New compounds and their use
GB0603376D0 (en) Compounds and their use
GB0610888D0 (en) Compounds and their use
GB0603374D0 (en) Compounds and their use
GB0619609D0 (en) Compounds and their use
GB0608846D0 (en) Compounds and their use
GB0616577D0 (en) Compounds and their use